Fig. 2From: Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the NetherlandsKaplan-Meier estimates of survival for patients treated in the third line with cetuximab or BSC. BSC, best supportive careBack to article page